Rituximab,Zanubrutinib in Combination With Lenalidomide, Followed by Zanubrutinib or Lenalidomide Maintenance in Patients With Primary or Secondary CNS Lymphoma
Clinical trial NCT04938297 · UNKNOWN
Trial details
- NCT number
- NCT04938297
- Sponsor
- Henan Cancer Hospital
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2021-05-26
- Primary completion
- 2022-10-31
- Enrollment
- 100
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.